| HOME >> BIOLOGY >> TECHNOLOGY |
Session ID: Poster Session A
Abstract Number: 6186
Poster Presentations at the 2007 AACR-NCI-EORTC Meeting
Tuesday, October 23rd, 12:30-2:30pm
Identification of Polo-like kinase 1 inhibitors through phenotype-based
approaches
Session ID: Small Molecule Therapeutic Agents: Kinase Inhibitors
Abstract Number: A234
Wednesday, October 24th, 12:30-2:30pm
Novel small molecule inhibitors of the Axl receptor tyrosine kinase block
tumor growth
Session ID: Small Molecule Therapeutic Agents: Kinase Inhibitors
Abstract Number: B230
Wednesday, October 24th, 12:30-2:30pm
Selective inhibitors of JAK2 kinase as potential therapeutic agents
Session ID: Small Molecule Therapeutic Agents: Kinase Inhibitors
Abstract Number: B235
Poster Presentation at Cytokines 2007 Meeting
Saturday, October 27th, 5:30-7:30pm
A class of small molecules that inhibit TNFa-induced survival and death
pathways via prevention of interactions between TNFaRI, TRADD and RIP1
Session ID: Poster Session 1
Abstract Number: 46
About Rigel (http://www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and
develops novel, small-molecule drugs for the treatment of
inflammatory/autoimmune diseases and cancer, as well as viral and metabolic
diseases. Our goal is to file one new investigational new drug (IND)
application in a significant indication each year. Rigel has achieved this
goal every year since 2002. Our pioneering research focuses on
intracellular signaling pathways and related targets that are critical to
disease mechanisms. Rigel's productivity has resulted in strategic
collaborations with large pharmaceutical partners to develop and market our
product candidates. Rigel has product development programs in
inflammatory/autoimmune diseases such as rheumatoid arthr
'/>"/>
| SOURCE Rigel Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |